FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Breakthrough, Orphan Drug Status for PellePharm Drug

FDA grants PellePharm a breakthrough therapy designation and orphan drug designation for topical patidegib for patients with Gorlin Syndrome.

Human Drugs

White House Puts 2015 Opioid Crisis Cost at $500 Billion

A new White House report estimates that the ongoing opioid crisis cost the U.S. $504 billion in 2015 and led to over 33,000 American overdose deaths.

Federal Register

Janssen Biosimilar Patent Infringement Complaint Filed

Federal Register notice: FDA acknowledges that an applicant for a proposed biosimilar product notified the agency that a patent infringement action wa...

Federal Register

Guide on UDI Direct Device Markings

Federal Register notice: FDA makes available a guidance entitled Unique Device Identification: Direct Marking of Devices.

Human Drugs

FDA Approves Kalos AUVI-Q for Infants

FDA approves a Kalo supplemental NDA for AUVI-Q (epinephrine injection, USP) 0.1 mg, for treating life-threatening allergic reactions, including anaph...

FDA General

Latest Federal Register Notices

FDA Review posts the Federal Register notices for the week ending 11/17/2017.

Federal Register

Guide on Cell/Tissue-Based Product Regulatory Considerations

FDA releases a guidance on Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Minimal Manipulation a...

Rep. DeLauro Seeks Ban on DTC Ads, Again

Congresswoman Rosa DeLauro (D-CT) reintroduces a bill (HR 4385) that would amend the Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug ...

Human Drugs

Docket Number Correction for ANDA Controlled Correspondence

Federal Register notice: FDA corrects an 11/3 Federal Register notice entitled Controlled Correspondence Related to Generic Drug Development.

Federal Register

Expedited Programs for Regenerative Medicines Draft Guidance

Federal Register notice: FDA makes available a draft guidance on Expedited Programs for Regenerative Medicine Therapies for Serious Conditions.